Advaxis, Inc. (ADXS)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 16.57 Million USD | -36.06% |
| 2022 | 25.93 Million USD | -44.57% |
| 2021 | 46.78 Million USD | 21.42% |
| 2020 | 38.52 Million USD | 92.11% |
| 2019 | 20.05 Million USD | -67.79% |
| 2018 | 62.26 Million USD | -33.51% |
| 2017 | 93.64 Million USD | -44.61% |
| 2016 | 169.04 Million USD | 41.33% |
| 2015 | 119.6 Million USD | 411.62% |
| 2014 | 23.37 Million USD | -0.88% |
| 2013 | 23.58 Million USD | 518.11% |
| 2012 | 3.81 Million USD | -32.35% |
| 2011 | 5.64 Million USD | 96.18% |
| 2010 | 2.87 Million USD | 5.93% |
| 2009 | 2.71 Million USD | 103.93% |
| 2008 | 1.33 Million USD | -75.62% |
| 2007 | 5.46 Million USD | 36.42% |
| 2006 | 4 Million USD | 37.83% |
| 2005 | 2.9 Million USD | 478.4% |
| 2004 | 502.08 Thousand USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q3 | 6.98 Million USD | -42.55% |
| 2023 Q2 | 12.15 Million USD | -42.12% |
| 2023 Q1 | 20.99 Million USD | 170.24% |
| 2023 FY | 16.57 Million USD | -36.06% |
| 2023 Q4 | 16.57 Million USD | 137.49% |
| 2022 Q3 | 25.93 Million USD | -13.86% |
| 2022 FY | 25.93 Million USD | -44.57% |
| 2022 Q4 | 7.76 Million USD | -70.04% |
| 2022 Q1 | 37.51 Million USD | -19.31% |
| 2022 Q2 | 30.1 Million USD | -19.77% |
| 2021 Q4 | 46.49 Million USD | -0.6% |
| 2021 Q3 | 46.78 Million USD | -3.49% |
| 2021 Q2 | 48.47 Million USD | -18.17% |
| 2021 FY | 46.78 Million USD | 21.42% |
| 2021 Q1 | 59.23 Million USD | 29.25% |
| 2020 Q2 | 60.27 Million USD | 297.54% |
| 2020 Q4 | 45.82 Million USD | 18.95% |
| 2020 FY | 38.52 Million USD | 92.11% |
| 2020 Q1 | 15.16 Million USD | -24.39% |
| 2020 Q3 | 38.52 Million USD | -36.08% |
| 2019 FY | 20.05 Million USD | -67.79% |
| 2019 Q4 | 20.05 Million USD | -55.69% |
| 2019 Q3 | 45.25 Million USD | -19.38% |
| 2019 Q2 | 56.13 Million USD | 12.78% |
| 2019 Q1 | 49.77 Million USD | -1.06% |
| 2018 Q2 | 61.05 Million USD | -22.88% |
| 2018 FY | 62.26 Million USD | -33.51% |
| 2018 Q1 | 79.16 Million USD | 2.23% |
| 2018 Q3 | 62.26 Million USD | 1.98% |
| 2018 Q4 | 50.3 Million USD | -19.21% |
| 2017 Q2 | 110.72 Million USD | -19.71% |
| 2017 Q1 | 137.89 Million USD | -9.4% |
| 2017 FY | 93.64 Million USD | -44.61% |
| 2017 Q4 | 77.44 Million USD | -17.3% |
| 2017 Q3 | 93.64 Million USD | -15.43% |
| 2016 Q1 | 104.3 Million USD | -7.49% |
| 2016 Q2 | 91.22 Million USD | -12.54% |
| 2016 Q4 | 152.19 Million USD | -9.97% |
| 2016 Q3 | 169.04 Million USD | 85.31% |
| 2016 FY | 169.04 Million USD | 41.33% |
| 2015 Q3 | 119.6 Million USD | 16.91% |
| 2015 Q2 | 102.3 Million USD | 97.94% |
| 2015 FY | 119.6 Million USD | 411.62% |
| 2015 Q4 | 112.74 Million USD | -5.73% |
| 2015 Q1 | 51.68 Million USD | 49.6% |
| 2014 Q1 | 30.86 Million USD | 63.02% |
| 2014 Q3 | 23.37 Million USD | -10.45% |
| 2014 Q2 | 26.1 Million USD | -15.42% |
| 2014 Q4 | 34.54 Million USD | 47.79% |
| 2014 FY | 23.37 Million USD | -0.88% |
| 2013 FY | 23.58 Million USD | 518.11% |
| 2013 Q1 | 4.56 Million USD | 20.47% |
| 2013 Q2 | 4.36 Million USD | -4.44% |
| 2013 Q3 | 23.58 Million USD | 440.54% |
| 2013 Q4 | 18.93 Million USD | -19.72% |
| 2012 Q1 | 3.78 Million USD | -21.78% |
| 2012 Q2 | 4.12 Million USD | 8.94% |
| 2012 Q3 | 3.81 Million USD | -7.46% |
| 2012 Q4 | 3.79 Million USD | -0.67% |
| 2012 FY | 3.81 Million USD | -32.35% |
| 2011 FY | 5.64 Million USD | 96.18% |
| 2011 Q4 | 4.83 Million USD | -14.21% |
| 2011 Q1 | 3.87 Million USD | 19.82% |
| 2011 Q3 | 5.64 Million USD | 18.7% |
| 2011 Q2 | 4.75 Million USD | 22.75% |
| 2010 Q2 | 2.57 Million USD | 25.76% |
| 2010 FY | 2.87 Million USD | 5.93% |
| 2010 Q4 | 3.23 Million USD | 12.37% |
| 2010 Q3 | 2.87 Million USD | 11.46% |
| 2010 Q1 | 2.05 Million USD | -29.64% |
| 2009 Q2 | 1.83 Million USD | 32.85% |
| 2009 Q1 | 1.38 Million USD | -9.38% |
| 2009 Q4 | 2.91 Million USD | 7.41% |
| 2009 Q3 | 2.71 Million USD | 48.02% |
| 2009 FY | 2.71 Million USD | 103.93% |
| 2008 FY | 1.33 Million USD | -75.62% |
| 2008 Q2 | 1.69 Million USD | -37.85% |
| 2008 Q4 | 1.52 Million USD | 14.44% |
| 2008 Q3 | 1.33 Million USD | -21.47% |
| 2008 Q1 | 2.72 Million USD | -35.35% |
| 2007 Q4 | 4.21 Million USD | -22.75% |
| 2007 Q1 | 1.98 Million USD | -38.78% |
| 2007 Q2 | 1.3 Million USD | -34.36% |
| 2007 Q3 | 5.46 Million USD | 319.39% |
| 2007 FY | 5.46 Million USD | 36.42% |
| 2006 Q4 | 3.23 Million USD | -19.06% |
| 2006 Q3 | 4 Million USD | -12.94% |
| 2006 Q1 | 4.91 Million USD | 85.56% |
| 2006 Q2 | 4.59 Million USD | -6.38% |
| 2006 FY | 4 Million USD | 37.83% |
| 2005 Q2 | 3.26 Million USD | -3.82% |
| 2005 Q4 | 2.64 Million USD | -8.86% |
| 2005 FY | 2.9 Million USD | 478.4% |
| 2005 Q3 | 2.9 Million USD | -11.03% |
| 2005 Q1 | 3.39 Million USD | -12.67% |
| 2004 FY | 502.08 Thousand USD | 0.0% |
| 2004 Q4 | 3.88 Million USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -717605.628% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -746.65% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -57.087% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -2902.789% |
| Rebus Holdings, Inc. | 5000.00 USD | -331480.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 87.268% |
| Qrons Inc. | 420.00 USD | -3947280.952% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -2051.318% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 40.671% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -3349.955% |
| Skye Bioscience, Inc. | 11.94 Million USD | -38.848% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 57.322% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -129.634% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -21613.335% |
| SQZ Biotechnologies Company | 107.18 Million USD | 84.533% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1057.726% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -22810.247% |
| Mesoblast Limited | 667.9 Million USD | 97.518% |
| Marizyme, Inc. | 22.01 Million USD | 24.693% |
| Genus plc | 1.02 Billion USD | 98.389% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1120.522% |
| Pharming Group N.V. | 462.85 Million USD | 96.418% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -400.421% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -3222.185% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -2544.179% |
| ContraFect Corporation | 20.67 Million USD | 19.827% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -4147.04% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -4238.042% |
| IMV Inc. | 31.33 Million USD | 47.089% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -299.877% |
| MultiCell Technologies, Inc. | 126.22 USD | -13134902.377% |
| ONE Bio Corp. | 70.08 Million USD | 76.345% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -1664.307% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 87.099% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -3740.274% |
| Q BioMed Inc. | 3.51 Million USD | -371.595% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 52.872% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -6245.373% |
| Biomind Labs Inc. | 73.81 Thousand USD | -22358.988% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 96.285% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -1044.292% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 44.764% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -503.677% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -2311.54% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -536.871% |
| GB Sciences, Inc. | 103.44 Thousand USD | -15927.339% |
| Alpha Cognition Inc. | 2.45 Million USD | -576.095% |
| HST Global, Inc. | 1526.00 USD | -1086335.125% |
| CSL Limited | 38.02 Billion USD | 99.956% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1578.092% |
| Halberd Corporation | 10.13 Thousand USD | -163546.234% |
| Enzolytics Inc. | 361.7 Million USD | 95.416% |
| Agentix Corp. | 261.39 Thousand USD | -6242.581% |
| Resverlogix Corp. | 8.11 Million USD | -104.301% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -782.857% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.635% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 65.245% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -2491.862% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -72675.559% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -85.258% |
| AVAX Technologies, Inc. | 7.37 Million USD | -124.734% |
| Zenith Capital Corp. | 7410.00 USD | -223638.192% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.51% |
| Ember Therapeutics, Inc. | 184.00 USD | -9010226.087% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -5051.862% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -6243.261% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1686.605% |
| Kadimastem Ltd | 2.3 Million USD | -619.55% |
| Helix BioMedix, Inc. | 3.02 Million USD | -448.051% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 68.541% |
| BioStem Technologies, Inc. | 14.56 Million USD | -13.864% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -28938.078% |
| LadRx Corporation | 2.3 Million USD | -618.364% |
| Cell Source, Inc. | 195.17 Thousand USD | -8394.602% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -4588.406% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -4588.406% |
| NovAccess Global Inc. | 62.24 Thousand USD | -26533.787% |
| Affymax, Inc. | 7.44 Million USD | -122.746% |
| Itoco Inc. | 1.4 Million USD | -1084.153% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -17231.716% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -15540.566% |
| Mobile Lads Corp. | 52.00 USD | -31882592.308% |
| CytoDyn Inc. | 11.13 Million USD | -48.878% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -11495.977% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -92623.714% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -4200.972% |
| SYBLEU INC | 330.46 Thousand USD | -4916.825% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -3949.367% |
| International Stem Cell Corporation | 5.39 Million USD | -207.588% |
| Bioxytran, Inc. | 137.63 Thousand USD | -11945.365% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -10.513% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -20886.076% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -1817.363% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -120.553% |
| Neutra Corp. | 2851.00 USD | -581415.258% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 48.84% |
| PureTech Health plc | 693.97 Million USD | 97.611% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -105.412% |
| IXICO plc | 15.84 Million USD | -4.64% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -100.181% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 83.954% |
| CSL Limited | 38.02 Billion USD | 99.956% |
| Cellectis S.A. | 333.99 Million USD | 95.036% |